WOBURN, Mass., Feb. 9, 2012 \/PRNewswire\/ -- MBL International Corporation, a leading life science company focused on providing high quality products and solutions for life science research and clinical diagnostics, today announced the launch of AngioPhase\u2122, an angiogenesis kit which allows for the analysis of all known phases of the angiogenic process in a convenient and flexible format. <\/p>\n
Angiogenesis is the multistep process whereby new blood vessels develop from pre-existing vasculature. It plays a key role in the natural process of healing and reproduction but also in many pathological processes including cancer, skin diseases, age-related blindness, diabetic ulcers, cardiovascular disease, and stroke. <\/p>\n
AngioPhase\u2122 incorporates a patented technology, developed by TCS Cellworks Limited, Buckingham, UK, in which human endothelial cells are co-cultured with other human cells in a specially designed medium. Under the terms of the non-exclusive agreement with TCS Cellworks Limited, MBL International Corporation has been granted a license to manufacture and sell the assay in North and South America. <\/p>\n
\"MBL International is excited about adding AngioPhase to our growing portfolio of life sciences products,\" said Dennis Walczewski, CEO MBL International Corporation. \"This technology offers many benefits to researchers in the biotechnology and pharmaceutical industries by offering a ready-to-use angiogenesis kit in which test compounds can be added at any time. Moreover, both angiogenic simulators and inhibitors can be assessed as well as tubule formation.\" <\/p>\n
\"We are pleased to enter into this licensing agreement with MBL International Corporation,\" stated Tim Almond CEO of TCS Cellworks. \"They have demonstrated not only a strong commitment to manufacturing high quality products but also an impressive business model which leverages the superior technical expertise of their commercial team.\" <\/p>\n
About MBL International Corporation <\/p>\n
MBL International Corporation is a leading life science company focused on providing high quality products and solutions for life science research and clinical diagnostics. Our products are used widely in academic research institutions, pharmaceutical and biotechnology companies, government agencies, as well as hospital and reference laboratories. By providing a consultative approach, superior technical and customer support, and convenient purchasing options, MBL International Corporation is your partner in solving your scientific and clinical challenges. <\/p>\n
For more information visit http:\/\/www.mblintl.com<\/a> or call 800-200-5459. <\/p>\n About TCS Cellworks Limited <\/p>\n TCS Cellworks is a UK based cellular biology company specializing in the development and application of human primary cell tissue models for the bioscience and pharmaceutical business sectors. The success of the AngioPhase kit in Europe is now being expanded to other markets through carefully selected business partners. TCS also acts as a distributor for a number of international manufacturers in the cell biology field. For further information visit http:\/\/www.tcscellworks.co.uk<\/a> or call 0044 1280 827475. <\/p>\n<\/p>\n See more here: WOBURN, Mass., Feb. 9, 2012 \/PRNewswire\/ -- MBL International Corporation, a leading life science company focused on providing high quality products and solutions for life science research and clinical diagnostics, today announced the launch of AngioPhase\u2122, an angiogenesis kit which allows for the analysis of all known phases of the angiogenic process in a convenient and flexible format. Angiogenesis is the multistep process whereby new blood vessels develop from pre-existing vasculature. Continue reading
\nMBL International Corporation Introduces AngioPhase\u2122 Angiogenesis Kit<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"